Investor Update: Ipca Laboratories Ltd. Q3 FY26 Performance Highlights

Ipca Laboratories has demonstrated robust financial resilience and operational efficiency for the quarter ended December 31, 2025. The company’s focus on a vertically integrated business model and strong market penetration has resulted in double-digit growth across key segments. Financial Overview The quarter was characterized by significant bottom-line outperformance, with profit growth substantially outpacing revenue expansion: Net Profit: Reported at ₹326.3 crore, representing a 31.5% YoY increase from ₹248 crore. Revenue from Operations: Grew 6.6% YoY to ₹2,392.5 crore, driven by steady demand in core markets. EBITDA: Increased by 15.2% to ₹533.7 crore, reflecting disciplined cost management and a favorable product mix. Operating Margins: Expanded by 170 basis points to 22.3%, up from 20.6% in the previous year. Segmental Performance Growth was broad-based, fueled by both domestic leadership and international expansion: Indian Formulations: Revenue rose 12% to ₹984 crore, maintaining strong traction within the domestic healthcare sector. Exports: International income climbed 13% to ₹770.49 crore, validating the company's global competitiveness in Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Market Position and Outlook Ipca Laboratories continues to leverage its status as a fully integrated pharmaceutical player. The expansion in margins during Q3 FY26 underscores the company's ability to drive operational efficiencies despite global inflationary pressures. Following the announcement, the market responded positively, with shares trading at ₹1,487.95 (up 0.85%) on the NSE, reflecting investor confidence in the company’s trajectory and fundamental strength.